Once we confirmed that RAC1 inhibition overcomes midostaurin resistance, we explored the effect of this combination in cells obtained from patients with refractory FLT3-ITD+ and FLT3-TKD + AML. Here, RAC1 is linked to acute myeloid leukemia.